The interaction between post-transplant anemia and allograft function in kidney transplantation: The Japan Academic Consortium of Kidney Transplantation-II study

Impact of immediate post‐transplant parenteral iron therapy on the prevalence of anemia and short‐term allograft function in a cohort of pediatric and adolescent renal transplant recipients

“…There is theoretical evidence of a vicious cycle in the relationship between late‐onset anemia and chronic allograft dysfunction. Anemia of EPO deficiency may result from impaired graft function, while there is a shorter graft survival that follows chronic anemia 3,32,33 . In our study, unlike the early transplant period, the non‐significant association of iron deficiency with anemia at 12 and 24 months may be due to the dominant effect of a deteriorating allograft function (Table 3b).…”

“…Anemia of EPO deficiency may result from impaired graft function, while there is a shorter graft survival that follows chronic anemia. 3,32,33 In our study, unlike the early transplant period, the non-significant association of iron deficiency with anemia at 12 and 24 months may be due to the dominant effect of a deteriorating allograft function (Table 3b). On the other hand, a longitudinal study of a large-sized pediatric cohort with late-onset anemia showed there was a subsequent shorter duration of graft survival and a higher mortality rate.…”

A Systematic Review and Meta-Analysis of Posttransplant Anemia With Overall Mortality and Cardiovascular Outcomes Among Kidney Transplant Recipients

“…We excluded 3 included studies in the previous meta-analysis due to using the impact of a 1 g/dL increase in hemoglobin level on outcomes. A total of 17 observational studies, 1–3,5–8,13–22 including 16 463 recipients, finally met the inclusion criteria and were included in the meta-analysis. Figure 1 outlines the selection process.…”

“…19 According to a stratification based on allograft function, the magnitude of difference in incidence of cardiovascular events between those with and without PTA was enhanced in low eGFR group. 19 Contrasting data were obtained from another randomized trial conducted by Schjelderup et al showing no correlation between hemoglobin levels and MACE after 7-year follow up. 22 It is worth noting that the results might be interfered by selection bias as kidney recipients treated with statin therapy, and hence those with established cardiovascular diseases, were not included in that study.…”

“…15 A multicenter observational study in Japanese kidney recipients conducted by Okumi et al demonstrated that PTA was associated with increased cardiovascular events but not cardiovascular death. 19 According to a stratification based on allograft function, the magnitude of difference in incidence of cardiovascular events between those with and without PTA was enhanced in low eGFR group. 19 Contrasting data were obtained from another randomized trial conducted by Schjelderup et al showing no correlation between hemoglobin levels and MACE after 7-year follow up.…”